Bluebird Bio, Inc. Appoints Ramy Ibrahim as Director
January 11, 2021 at 08:05 am EST
Share
On January 5, 2021, the board of directors of bluebird bio, Inc., upon the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Ramy Ibrahim, M.D. as a director of the company’s Board, effective January 7, 2021. Dr. Ibrahim will serve as a Class I director, to serve until the company’s annual meeting of stockholders in 2023. Dr. Ibrahim was also appointed to serve on the Nominating and Corporate Governance Committee of the Board. He is currently serving as a consultant for the Parker Institute for Cancer Immunotherapy (PICI) where he was recently the Chief Medical Officer and built the clinical capabilities within the institute as well as worked with renowned cell therapy experts to support building world class cell therapy startups.
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
BLUEBIRD BIO, INC. 
